ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET

Company Participants

Joe Burnett - CEO

Danilo D'Alessandro - CFO

Conference Call Participants

Nelson Cox - Lake Street Capital

William Wood - B. Riley

Operator

Greetings, and welcome to the ClearPoint Neuro, Inc. Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company's plans, prospects and strategies, both preliminary and projected, the size of total addressable markets or the market opportunity for the company's products and services, management's expectations, beliefs, estimates or projections regarding future results of operations.

Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for new information or future events. For more information, please refer to the company's annual report on Form 10-K for the year ended December 31, 2022, and the company's quarterly report on Form 10-Q for the three months ended March 31, 2023, both of which have been filed with the Securities and Exchange Commission and the company's quarterly report on Form 10-Q for the three months ended June 30, 2023, which the company intends to file with the Securities and Exchange Commission on or before August 14, 2023. All the company's filings may be obtained on the SEC or the company's website at www.clearpointneuro.com.

I would now like to turn the call over to your host, Joe Burnett, Chief Executive Officer. Please go ahead.

Joe Burnett

Thank you, and thank you to all of the investors and analysts on today's call. And thank you also for being a part of ClearPoint vision and journey. Our mission and our priority is to help restore quality of life to patients and their families, who are suffering from some of the most debilitating neurological disorders imaginable.

In the second quarter of 2023, the company returned to double-digit growth and delivered record revenue of $6 million in the quarter. We have also continued to make progress across our 4-pillar growth strategy, including Pillar 1, biologics and drug delivery; Pillar 2, functional surgery navigation; Pillar 3, therapy and access products; and Pillar 4, achieving global scale.

I will now turn the call over to Danilo D'Alessandro, our CFO, to review our financial performance in the quarter, after which I will add some detail to our 4-pillar growth strategy and expectations for the second half of 2023. Danilo?